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Abstract (85 words): Streptococcus pyogenes (group A streptococcus) causes human skin and
throat infections as well as highly invasive diseases including necrotising fasciitis. Group A
streptococcal infections and invasive disease have made a resurgence in developed countries
over the last two decades. S. pyogenes utilise multiple pathways for the acquisition and
activation of human plasminogen, securing potent proteolytic activity on the bacterial cell
surface. Recent experimental evidence using a humanised transgenic mouse model suggests a
critical role for human plasminogen in the dissemination of S. pyogenes in vivo.

Invasive diseases caused by S. pyogenes: Group A streptococcus (Streptococcus pyogenes)
causes a variety of illnesses with diverse clinical manifestations (see text box) [1]. Since the mid1980’s, there has been a global resurgence of severe invasive group A streptococcal infections
[2-4]. These diseases progress rapidly and are associated with high rates of morbidity and
mortality despite the prompt use of antibiotics. Infection rates have persisted over the last 20
years which has spurred new research into identifying host susceptibility factors and bacterial
determinants that may explain these epidemiological changes.

Although no single group A streptococcal virulence determinant has been exclusively associated
with a specific disease type, early research identified an association between certain M protein
serotypes (i.e. M1 and M3) and invasive infections [5]. Numerous other studies from the 1990’s
suggested that the resurgence of invasive group A streptococcal infections was due to the
emergence of “highly virulent” strains that were clonal in origin [6-11]. Nonetheless, more
recent studies examining larger strain sets and using more powerful methodologies to
characterise the subtle genetic diversity among isolates have failed to demonstrate a significant
association between any particular group A streptococcal clone and invasive infections [12].
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S. pyogenes strains of M1T1 and M3 serotypes can be isolated from both uncomplicated
infections such as pharyngitis and severe invasive infections such as necrotising fasciitis [5,13].
These group A streptococcal strains can also vary greatly in disease frequency and exhibit
epidemic behaviour suggesting these strains are capable of rapid genetic change. Beres et al. [14]
found that the major generator of distinct genotypes within 255 group A streptococcal strains
(serotype M3) was the acquisition and loss of prophages encoding known and putative virulence
factors. This molecular process combined with altered immune recognition due to a four amino
acid change in the N-terminal region of the M protein is believed to have significantly
contributed to an epidemic wave of M3 invasive infections [14]. Phage sequences present in the
two sequenced M3 genomes have also been detected in the genome of S. pyogenes M1T1, a
strain that is often isolated from invasive diseases [15]. The genetic mosaicism and unique gene
sequences present in these phage cassettes act as additional sources of genetic variability and
suggest phages can be shared between different M serotypes and even different bacterial species
[15]. Host genetic factors have also been shown to play an important role in determining the
severity of invasive group A streptococcal infections by altering the magnitude of the cytokine
and inflammatory responses against secreted streptococcal pyrogenic exotoxins [16,17].

Common to all invasive group A streptococcal diseases is the requirement of the bacteria to gain
entry into areas of the body that are normally sterile sites. Plasminogen binding and its activation
to the broad-spectrum serine protease plasmin has been implicated as a contributing mechanism
of invasion for S. pyogenes and a variety of other bacterial species [18,19].

Binding of plasminogen to the group A streptococcal cell surface: Plasminogen is the
multidomain, 791 amino acid circulating zymogen form of plasmin. Plasminogen contains five
kringle domains with lysine-binding sites identified in kringles 1, 2, 4 and 5 which are
responsible for binding to fibrinogen and plasminogen receptors [20]. Two pathways have been
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described in the literature for the binding of plasminogen to the group A streptococcal cell
surface. Direct plasminogen binding is meditated by the three known surface plasminogen
receptors: plasminogen-binding group A streptococcal M-like protein (PAM or M53; [21]), αenolase (surface enolase or SEN; [22]) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), alternatively known either as plasminogen receptor (Plr) or streptococcal surface
dehydrogenase (SDH) [22,23]. Additionally, indirect binding of plasminogen is mediated by the
formation of a trimolecular complex consisting of plasminogen, streptokinase and fibrinogen.
This complex is then bound to the group A streptococcal cell surface via either plasminogen or
fibrinogen receptors [24-26].

Of the three known plasminogen receptors, published evidence suggests that PAM makes the
largest contribution to direct plasminogen binding by group A streptococci. In two independent
studies, PAM-positive S. pyogenes isolates have been found to bind significantly higher levels of
plasminogen than PAM-negative isolates [26,27] (Figure 1A). Svensson et al. [27] found an
association between PAM-positive isolates and impetigo. Nonetheless, in a study of group A
streptococcal isolates from the Northern Territory of Australia where skin infections are
endemic, PAM-positive isolates were found to cause bacteremia, throat and skin infections [26].
Binding of PAM to plasminogen is mediated by amino-terminal plasminogen-binding tandem
repeat motifs containing lysine residues (designated a1 and a2) in the PAM molecule, which
interact with the lysine binding kringle 2 domain of plasminogen [21,28,29].

Plasminogen has been reported to bind to cell-surface located glycolytic enzymes α-enolase and
GAPDH [22,23]. Both GAPDH and α-enolase interact with lysine binding kringles domain of
plasminogen via carboxy-terminal lysine residues [22,30]. Such carboxy-terminal lysine residues
usually bind to kringle 1, 4 and 5 of plasminogen [20]. Whilst α-enolase has been described as a
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high affinity plasminogen receptor [22], the failure of PAM-negative isolates to bind significant
levels of plasminogen by the direct binding pathway [26,27] suggests that α-enolase may play a
more prominent role in the indirect binding pathway by interacting with a trimolecular complex
consisting of plasminogen, streptokinase and fibrinogen (Figure 1A). GAPDH has been reported
to bind plasminogen with low affinity [22]. Neither GAPDH nor α-enolase contain known
secretion signals or membrane anchor motifs and the mechanism by which these glycolytic
enzymes become surface exposed is unknown. Both enzymes have also been detected in S.
pyogenes culture supernatants [31,32]. Other researchers have suggested hypotheses to account
for cell-surface GAPDH and α-enolase including the release of such proteins from group A
streptococcal cells by autolysis with the released protein potentially binding back to the surface
of neighbouring cells or the existence of a hitherto uncharacterised transport mechanism [22,33].
Recently, asymmetric protein secretion of streptococcal pyrogenic exotoxin B (SpeB) was shown
to occur at distinct cytoplasmic membrane microdomains termed ExPortals [34]. The role that
this structure plays in the secretion of other S. pyogenes proteins is currently unknown. However,
GAPDH and α-enolase are also asymmetrically distributed on the GAS cell surface [22,33,35],
reminiscent of the distribution of SpeB at the GAS ExPortal (Figure 2). We therefore
hypothesise that both GAPDH and α-enolase are secreted from the group A streptococcal cell
via the ExPortal then subsequently bind to the cell surface.

As mentioned above, the indirect plasminogen-binding pathway in S. pyogenes requires
streptokinase and fibrinogen [24,25,36] (Figure 1A). Takada and Takada [36] first reported the
capacity of plasminogen, fibrinogen and streptokinase to form a trimolecular complex. This
complex, which forms extracellularly then binds to the surface of group A streptococci,
possesses both plasmin [25] and plasminogen-activator [37] activities. This pathway may
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represent the primary plasminogen surface-acquisition mechanism in PAM-negative S. pyogenes
isolates.

Acquisition of surface plasmin: The conversion of plasminogen to plasmin can be achieved by
either the mammalian plasminogen activators urokinase (uPA) and tissue plasminogen activator
(tPA), or by secreted microbial activators such as streptokinase [19,20]. As distinct from tPA or
uPA, which directly cleave the plasminogen activation bond (i.e. Arg561-Val562) to generate
plasmin, streptokinase has no protease activity and cannot directly cleave this bond. Instead,
streptokinase forms a 1:1 complex with plasminogen. The preferred catalytic substrate of this
complex is the activation loop of other plasminogen molecules [38]. Plasminogen bound to the
group A streptococcal surface can also interact with streptokinase leading to bacterium bound
plasmin activity [25,37,39]. Additionally, tPA and uPA have been shown to activate
plasminogen bound to the group A streptococcal surface [21,40] (Figure 3A). The streptokinaseplasminogen activator complex and surface-bound plasmin cannot be inhibited by host plasmin
inhibitors (i.e. α2-antiplasmin and α2-macroglobulin) [19,41]. This suggests a propensity of S.
pyogenes for unregulated plasminogen activation capacity and plasmin activity regardless of host
inhibitors.
However, Tewodros et al. [42] found no correlation between secreted streptokinase activity in
vitro and disease manifestation. Furthermore, high plasminogen binding strains were found to
secrete low levels of streptokinase activity [42] (Figure 1B). Phylogenetic analysis of the βdomain region of the gene encoding streptokinase (ska) revealed 2 major sequence clusters
(clusters 1 and 2) [43]. Most PAM-positive strains possess the subcluster 2b ska allele. PAMnegative strains fall into either cluster 1 or subcluster 2a ska alleles [43]. Interestingly, PAMpositive strains are high plasminogen binders and acquire streptokinase-dependent and/or tPAdependent surface plasmin activity (Figure 1C) yet secrete low levels of active streptokinase [39]
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(Figure 1B). The lack of streptokinase activity is possibly attributable to the expression of the
cysteine protease SpeB in stationary phase cultures which degrades streptokinase [39]. On the
other hand, relatively high levels of active streptokinase are secreted by low plasminogen
binding strains [42] (Figure 1B). An alternative explanation for these observations may be
related to the various ska alleles. Kalia and Bessen [43] proposed that subcluster 2b forms of
streptokinase have adapted for interaction with plasminogen in the open conformation induced
by binding to PAM rather than the closed circulating form of plasminogen (i.e. in solution phase)
preferred by the other subcluster forms of streptokinase (Figure 3B and 3C, respectively). Thus,
if subcluster 2b forms of streptokinase can only form streptokinase-plasminogen activator
complexes when surface bound to PAM, this may account for the apparent lack of streptokinase
activity in the supernatants of PAM-positive strains (Figure 1B). Non-cluster 2b forms of
streptokinase may interact with both free and surface-bound forms of plasminogen (Figure 3C).

Contribution of plasmin to the dissemination of S. pyogenes: The importance of plasminogen
in streptococcal pathogenicity is defined by the biochemical and molecular evolution of
streptococcal plasminogen activation. The interaction of streptokinase with plasminogen reflects
the mammalian host range of various streptococcal species [44] [45]. The species specificity of
plasminogen activation and its importance in virulence are exemplified in murine models of
group A streptococcal infection, where murine plasminogen is resistant to activation by S.
pyogenes streptokinase [46] and mice are generally resistant to skin infection with S. pyogenes
[47]. Accordingly, a high streptokinase-producing S. pyogenes strain and its streptokinasedeletion mutant show no difference in virulence in a mouse skin infection model [48]. In
contrast, when a source of human plasminogen is present at the infection site, the presence of the
streptokinase gene markedly enhances group A streptococcal virulence [39,48]. Likewise,
virulence of streptokinase-producing S. pyogenes is enhanced in the mouse by preincubation in
human plasma, but not plasminogen-depleted plasma [49].
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The recently developed humanised plasminogen transgenic mouse model of infection
definitively demonstrated the critical role of human plasminogen in group A streptococcal
pathogenicity in vivo. The presence of a human plasminogen transgene markedly increased
mortality following skin infection with S. pyogenes, but not intravenous infection. The
susceptibility conferred by the human plasminogen transgene is dependent on streptokinase
secretion by S. pyogenes, and is characterized by enhanced bacterial dissemination. Fibrinogen
may be essential to host defense against group A streptococcal skin infection, possibly due to
encapsulation of the bacteria within fibrin networks and prevention of systemic access by
occlusion of the local vasculature. Acquisition of fibrinolytic activity by S. pyogenes
circumvents fibrin-dependent mechanisms, even if only transiently, thereby enhancing virulence
[47].

Even in the absence of streptokinase, the ability to focus plasminogen at the group A
streptococcal surface via cell-surface receptors enhances virulence in vivo. A streptokinasedeficient S. pyogenes strain with plasminogen-binding capacity showed enhanced virulence
when a human plasminogen source was provided, probably due to plasmin formation by host
activators, tPA or uPA [48]. Human plasminogen is more readily activated by murine tPA than is
murine plasminogen [46]. The binding of plasminogen to S. pyogenes is known to markedly
increase the rate of plasminogen activation by tPA [40] supporting the hypothesis that cellsurface binding of plasminogen is an important component of group A streptococcal
pathogenesis.

Conclusion: Current knowledge of the mechanisms of plasmin(ogen) binding to the S. pyogenes
cell surface, the activation of surface acquired plasminogen and the contribution of this protease
to the dissemination of group A streptococci in vivo suggests plasmin(ogen) plays an important
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role in invasive disease progression. Elucidation of the mechanism(s) by which human
plasminogen is bound to the group A streptococcal surface and activated may reveal new targets
for therapeutic intervention and the control of invasive disease.
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Figures and Text Box

Figure 1. Plasminogen binding and activation by PAM-positive and PAM-negative S. pyogenes
isolates. (A) Group A streptococcal binding of
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I-plasminogen alone (hatched bars) or in the

presence of excess streptokinase and fibrinogen (filled bars; data from [26]). (B) Streptokinase
activity in THY culture supernatants (A600 = 1.1). Similar data were obtained at A600 = 0.6
(results not shown). (C) Group A streptococcal cell-surface plasmin activity following 3h
incubation in plasma (filled bars) or plasminogen-depleted plasma (hatched bars). Streptokinase
alleles for each strain were as follows: NS53, subcluster 1; NS13, subcluster 2b; NS32,
subcluster 2b; NS931, subcluster 1; NS730, subcluster 1; NS474, subcluster 1. All measurements
represent mean (± SD) of triplicate determinations.

Figure 2. Immuno-electron microscopy revealing the asymmetric distribution of SpeB [34], SEN
[22,33] and GAPDH [33,35] on the GAS cell surface. Clusters of immuno-gold particles are boxed.

Figure 3. Schematic diagram summarising the possible pathways of cell surface plasmin
acquisition by various S. pyogenes strains. Plasminogen is a single chain 791 amino acid
glycoprotein containing seven distinct structural domains, which are designated the amino-terminal
peptide (NTP) followed by Kringles 1–5 (K1-5) and the carboxy terminal serine protease domain
(PD). K1, K2, K4 and K5 contain lysine-binding motifs that are responsible for binding to
fibrinogen and to plasminogen receptors. Lysine-dependent interaction/s between the NTP and K5
are also responsible for maintaining the circulating zymogen in a mostly closed, activation-resistant
form. As summarised here, the efficient conversion of plasminogen to its activated twin-chain form
plasmin (depicted by loss of the NTP and by the green coloured PD linked to the kringle domains
via a disulphide bond shown in red) by mammalian or microbial activators requires a bindinginduced conformational change in plasminogen to an open, activation-susceptible form [20,38,50].
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(A). Plasminogen bound directly to the cell surface via PAM, or other plasminogen receptors (PLR), or indirectly via fibrinogen receptors (F-R; not shown) may be activated to plasmin by host
activators. (B) Streptokinase contains three structural domains designated the α, β and γ domains,
all of which can bind to the PD resulting in the streptokinase-plasminogen activator complex.
Generally PAM negative strains secrete subcluster 1 or 2a allele forms of streptokinase [43] which
can readily interact with solution phase (free), closed plasminogen (via K5; [50]). This results in a
free activator complex that can convert other free plasminogen molecules to plasmin that can then
readily bind to the cell surface directly via plasmin(ogen) receptors (e.g. SEN, GAPDH).
Alternatively, the activator complex can bind to fibrinogen to form the fibrinogen-streptokinaseplasminogen trimolecular complex. This can then bind to the cell surface via fibrinogen receptors
and act on either directly or indirectly bound plasminogen leading to cell surface plasmin. (C) Most
PAM-positive strains secrete subcluster 2b allele forms of streptokinase (hatched) which
preferentially interact with an open conformation of plasminogen that is induced by binding to
PAM via K2. The PAM-bound activator complex can then either activate free plasminogen to
plasmin that can readily bind to the cell surface (via PAM and/or other receptors not shown here),
or other PAM-bound plasminogen to plasmin. In both cases, this results in cell surface bound
plasmin. Although not shown here, the PAM-bound activator complex could also act on indirectly
bound plasminogen (via fibrinogen receptors). In all scenarios, bound plasmin is resistant to
inhibition by α2-antiplasmin. In addition, free or PAM-bound streptokinase-plasminogen activator
complex, as well as the trimolecular activator complex, are resistant to inhibition by α2antiplasmin.
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Text Box:
Classification of group A streptococcal infection.
I. Streptococcal toxic shock syndrome (STSS): Defined as a definite case by isolation of group
A streptococci from a normally sterile site (eg. blood cerebrospinal, pleural or peritoneal fluid,
tissue biopsy, surgical wound etc.) or a probable case if isolated from a non-sterile site (eg.
Throat, sputum, vagina, superficial skin lesion etc.) in conjunction with combinations of the
following signs of clinical severity; hypotension, renal impairment, coagulopathy, increased
liver activity, adult respiratory distress syndrome, generalised erythematous rash or soft-tissue
necrosis.
II. Other invasive infections: Defined by isolation of group A streptococci from a normally
sterile site in patients not meeting criteria for STSS
a. Bacteremia with no identified focus
b. Focal infections with or without bacteremia. Includes meningitis, pneumonia,
peritonitis, puerperal sepsis, osteomyelitis, septic arthritis, necrotizing fasciitis,
surgical wound infections, erysipeas and cellulitis.
III. Scarlet Fever: Defined by a scarletina rash with evidence of group A streptococcal infection,
most commonly pharyngotonsillitis.
IV. Non-invasive infections: Defined by the isolation of group A streptococci from a non-sterile
site.
a. Mucous membrane: includes pharyngitis, tonsillitis, otitis media, sinusitis, vaginitis
b. Cutaneous: includes impetigo.
V. Non-suppurative sequelae: Defined by specific clinical findings with evidence of a recent
group A streptococcal infection
a. Acute rheumatic fever
b. Acute glomerulonephritis
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